We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has turned down a new drug application from Blueprint Medicines for Ayvakit (avapritinib) for treatment of adults with unresectable or metastatic fourth-line gastrointestinal stromal tumor (GIST). Read More
FDA drug approvals were down 16 percent in 2019 compared with 2018, a reduction that predates the COVID-19 outbreak, according to data and analytics firm GlobalData. Read More